Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Interim Commissioner: Manager or Scientist?

Executive Summary

FDA Chief Scientist Frank Torti fits the profile of an interim commissioner if the incoming administration wants a caretaker with a solid scientific stature and also little baggage of the past regime
Advertisement

Related Content

FDA Chief Scientist Post A Chance For Califf To Make Mark
Frank Torti’s Next 100 Days: Active, Not Just Acting FDA Commissioner
FDA’s Torti Tapped As Acting Commissioner; Interim Heads Also Named For HHS, CMS
REMS Cannot Rescue Imagify: Clear Product Benefit Needed To Convince FDA
REMS Cannot Rescue Imagify: Clear Product Benefit Needed To Convince FDA
FDA’s Von Eschenbach Returns To Texas In January; Will He Also Return To MD Anderson?
No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama
Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
FDA's Schwetz Is Acting Commissioner: RU-486 Appears To Be Touchstone
Advertisement
UsernamePublicRestriction

Register

PS050471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel